Brief: Nevro Corp Enrolls First Patient In PDN Sensory Study
24/04/2023 23:19
April 24 (Reuters) - Nevro Corp NVRO.N :
* NEVRO ANNOUNCES ENROLLMENT OF FIRST PATIENT IN PDN SENSORY
STUDY
* NEVRO CORP - FDA HAS GRANTED BREAKTHROUGH DEVICE
DESIGNATION FOR
PDN SENSORY STUDY AND POTENTIAL DEVICE INDICATION
Source text for Eikon: ID:nPn6P6FKza
Further company coverage: NVRO.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nevro
See all newsNevro Corp reports results for the quarter ended December 31 - Earnings Summary
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 77 cents a share - Earnings Preview
Nevro Corp expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Altus Power, Amazon, Nevro